石四药集团(02005.HK)两产品获准登记成为原料药

阿斯达克财经07-18

石四药集团(02005.HK) 公布，集团的苯甲酸阿格列汀及盐酸倍他司汀已获中国药品监督管理局批准登记成为在上市制剂使用的原料药。

苯甲酸阿格列汀是降糖药，主要用于治疗2型糖尿病。盐酸倍他司汀是血管扩张药，主要用于治疗内耳眩晕症、脑供血不足引起的眩晕、头晕、呕吐或耳鸣等。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-17 16:25。)

AASTOCKS新闻

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2452162274?lang=zh_CN&edition=full","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190604131528273_s.jpg","is_english":false,"pubTime":"2024-07-18 00:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2452162274","market":"other","top_or_hot":-1,"title":"石四药集团(02005.HK)两产品获准登记成为原料药","media":"阿斯达克财经","content":"<html><body><div> <span> <p><a href=\"https://laohu8.com/S/02005\">石四药集团</a>(02005.HK)<span> </span>公布，集团的苯甲酸阿格列汀及盐酸倍他司汀已获中国药品监督管理局批准登记成为在上市制剂使用的原料药。<br/><span></span><br/>苯甲酸阿格列汀是降糖药，主要用于治疗2型糖尿病。盐酸倍他司汀是血管扩张药，主要用于治疗内耳眩晕症、脑供血不足引起的眩晕、头晕、呕吐或耳鸣等。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-17 16:25。)</p><div></div>AASTOCKS新闻 </span> </div></body></html>","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>石四药集团(02005.HK)两产品获准登记成为原料药</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n石四药集团(02005.HK)两产品获准登记成为原料药\n</h2>\n\n<h4 class=\"meta\">\n\n<p class=\"head\">\n<strong class=\"h-name small\">阿斯达克财经</strong><span class=\"h-time small\">2024-07-18 00:44</span>\n</p>\n\n</h4>\n\n</header>\n<article>\n<html><body><div> <span> <p><a href=\"https://laohu8.com/S/02005\">石四药集团</a>(02005.HK)<span> </span>公布，集团的苯甲酸阿格列汀及盐酸倍他司汀已获中国药品监督管理局批准登记成为在上市制剂使用的原料药。<br/><span></span><br/>苯甲酸阿格列汀是降糖药，主要用于治疗2型糖尿病。盐酸倍他司汀是血管扩张药，主要用于治疗内耳眩晕症、脑供血不足引起的眩晕、头晕、呕吐或耳鸣等。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-17 16:25。)</p><div></div>AASTOCKS新闻 </span> </div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1364400/latest-news/AAFN\">阿斯达克财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02005","symbol_name":"石四药集团","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1364400/latest-news/AAFN","article_id":"2452162274","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190604131528273_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2452162274","pubTimestamp":1721234640,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"石四药集团(02005.HK) 公布，集团的苯甲酸阿格列汀及盐酸倍他司汀已获中国药品监督管理局批准登记成为在上市制剂使用的原料药。苯甲酸阿格列汀是降糖药，主要用于治疗2型糖尿病。盐酸倍他司汀是血管扩张药，主要用于治疗内耳眩晕症、脑供血不足引起的眩晕、头晕、呕吐或耳鸣等。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-17 16:25。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02005":"石四药集团","BK1191":"制药"},"translate_title":"Two products of Shisi Pharmaceutical Group (02005. HK) were approved for registration as APIs","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02005":1},"content_text":"石四药集团(02005.HK) 公布，集团的苯甲酸阿格列汀及盐酸倍他司汀已获中国药品监督管理局批准登记成为在上市制剂使用的原料药。苯甲酸阿格列汀是降糖药，主要用于治疗2型糖尿病。盐酸倍他司汀是血管扩张药，主要用于治疗内耳眩晕症、脑供血不足引起的眩晕、头晕、呕吐或耳鸣等。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-17 16:25。)AASTOCKS新闻","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2452162274"}